Sphere 3D Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sphere 3D Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.18M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.61M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $21.91M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.08M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $3.72M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $5.58M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $9.03M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $12.60M | Apr 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $81.52M | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | $76.39M | Mar 21, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.96M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $2.66M | Mar 13, 2024 |
| FY2019 | Dec 31, 2019 | $1.85M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $1.68M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.15M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $22.34M | Mar 21, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.48M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.47M) | Mar 27, 2026 |
| FY2022 | Dec 31, 2022 | ($192.80M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($17.29M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($4.28M) | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($26.21M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($26.18M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($68.46M) | Mar 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.00M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($21.41M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($30.00M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($157.65M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($19.72M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($6.02M) | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($12.62M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($18.07M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($63.82M) | Mar 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $1.03M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $605.0K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $971.0K | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $2.05M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $3.43M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $5.87M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.79M | Mar 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.12M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.58M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($6.58M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($30.77M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($28.52M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($1.81M) | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($7.62M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($8.97M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($17.47M) | Mar 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.50M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $8.94M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.56M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $17.63M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $102.24M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $0 | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $56.0K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $123.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $237.0K | Mar 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.12M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $43.23M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $45.66M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $83.02M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $275.92M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $8.41M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $11.29M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $83.28M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $92.56M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.35M | Mar 13, 2024 |
| FY2023 | Dec 31, 2022 | $11.98M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $6.30M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $7.17M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $16.89M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $72.82M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $72.11M | Mar 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.30M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $39.32M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $26.52M | Mar 27, 2026 |
| FY2023 | Dec 31, 2022 | $34.87M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $227.28M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $1.24M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($5.61M) | May 14, 2020 |
| FY2019 | Dec 31, 2017 | $10.46M | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $20.45M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $68.14M | Mar 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.39M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $1.39M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.39M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $863.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $44.13M | Mar 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($478.30M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($456.82M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($447.37M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($419.73M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($215.20M) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | ($191.60M) | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($187.32M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($161.43M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($135.24M) | Mar 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.43M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $586.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.34M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $54.36M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $149.0K | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $341.0K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $600.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.06M | Mar 21, 2018 |
| FY2017 | Dec 31, 2015 | $8.66M | Mar 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (20) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (20) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.39M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 2.55M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 15.37M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 9.80M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 63.57M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | 2.22M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | 889,461 | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 889,461 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 2.66M | Mar 21, 2018 |